Health Tennessee Oncology Study Shows Next-Generation KRAS Therapy Cuts Lung Cancer Death Risk by 44% October 26, 2026 Researchers at Tennessee Oncology contributed to a global Phase III clinical trial that revealed an investigational targeted therapy extended overall survival compared with currently approved treatments for patients with previously…